Drug Therapy for Alzheimer’s

Drug therapy options for patients with Alzheimer’s disease do not offer a treatment for the disease itself, but they help patients manage with the symptoms and in some cases may provisionally slow down the progression of the illness.

The first kind of drug used to treat Alzheimer’s disease is a class of medications called “cholinesterase inhibitors.” Drugs in this class are the most commonly prescribed to patients. The first cholinesterase inhibitor was approved by the FDA in 1996 and is called donepezil, or its brand name Aricept. In 2000, rivastigmine, brand name Exelon was approved. Galatamine was permitted for treatment in 2001. Its original brand name was Reminyl, but in 2005, it was renamed Razadyne.

Cholinesterase inhibitors work by blocking the breakdown of acetylcholine in the brain. Acetylcholine is a chemical messenger that helps the brain in maintaining memory and process information. Only about half of the patients taking cholinesterase see any improvement in brain function, and these patients only see modest improvement. This is because although the medications help keep acetylcholine levels high, they cannot prevent cell damage from spreading. Finally, the damaged cells will not be able to make use of the acetylcholine. In early stage Alzheimer’s disease, however, these medications sometimes can delay the deterioration process.

Doctors sometimes prescribe Vitamin E because it is suspected that its antioxidant powers can help protect the brain from a certain amount of weakening. Results of clinical trial have not proven Vitamin E to be irrefutably effective. Patients should not add Vitamin E unless they are advised to do so by a doctor. Too much Vitamin E can cause harm to the heart, and Vitamin E in general is not secure for people who take blood-thinning medications.

A single drug called Mematine, or its brand name Namenda, was approved in October, 2003 for moderate to severe Alzheimer’s disease. Mematine is in a class of drugs called “uncompetitive low to moderate affinity N-methyl-D-aspertate (NMDA) receptor antagonist.” Mematine is the only drug of its kind currently on the market in the US . Unlike the cholinesterase inhibitors, Mematine works by suppressing the activity of the chemical messenger glutamate in the brain. A certain amount of glutamate is needed to help the brain store and retrieve memories, as well as process information. This is achieved when the glutamate signals a cell to allow calcium into the cell, which in turn stimulates memory. However, extra glutamate in the brain signals the cells to allow too much calcium to penetrate. Too much calcium in the cells causes the cell to die, increasing the damage to the brain. Studies into the effectiveness of Mematime have shown mixed results. The most significant improvement, or slowing of deteriorating, has been shown in patients taking both Mematine and one of the cholinesterase inhibitors.

Additionally to the drugs that aim to address to brain chemistry causing Alzheimer’s disease, doctors often prescribe drugs that address the particular symptoms. A number of antidepressants and anti-anxiety medications can be given to Alzheimer’s patients, including Zoloft, Celexa, Prozac, and Ativan. As Alzheimer’s progresses, patients may experience hallucinations or become overly aggressive. In these instances, doctors often will prescribe antipsychotic medications, such as Zyprexa, Seroquel, and Clozaril.

Sleep disorders can often be a problem with Alzheimer’s disease; however sedatives tend to cause unsteadiness and agitation and are generally avoided if at all possible.

Clinical trials are always available to Alzheimer’s patients, occasionally offering them a chance to try new treatment options. Of course, participation in a clinical trial offers no guarantee that the patient will be in the group who is receiving medication. There is naturally a definite amount of risk involved in trying new medications, but patients are under medical supervision at all times. Doctors or the local chapter of the Alzheimer’s Association can direct patients in finding studies to join, treat some behavioral problems with Alzheimer’s disease.

Manufacturers touting “cure-all” Alzheimer’s tonics make tempting claims, but these claims should be treated with doubt. Patients should never take a medicine without informing their doctors. Some of these medications may simply be ineffective, while others may actually be risky.

What is Alzheimer’s?
What is Alzheimer’s? Patients often attribute the symptoms of Alzheimer’s to simply “getting old,” or in most cases, they may be ... what-is-alzheimers.php

Alzheimer’s medications
The ability to treat some forms of dementia highlights the importance of patients seeing a doctor soon after the appearance of their ... alzheimers-medications.php

Alzheimer’s cures
Being diagnosed with Alzheimer’s disease is scary for patients and their loved ones. The diagnosis means that life will change ...

Alzheimer’s care
Alzheimer’s is one of the more difficult diseases for families to care for. That is why more and more people are turning to what’s ... alzheimers-care.php

Dementia Alzheimer’s disease
Dementia is best described as a loss of intellectual or cognitive (thinking) functions within the brain. Those who suffer dementia ... dementia-alzheimers-disease.php



Site menu


More articles